Prognostic role of long non-coding RNA XIST expression in patients with solid tumors: a meta-analysis

Abstract

BackgroundThe aberrant expression of long non-coding RNA (lncRNA) X inactivate-specific transcript (XIST) has been demonstrated to be involved in the tumourigenesis and the development of various cancers. Therefore, we conducted a meta-analysis to assess the prognostic role of lncRNA XIST expression in solid tumors.MethodsThe databases of PubMed, EMBase, Web of Science, Cochrane library (up to Dec 31, 2017) were searched for the related studies and identified 15 eligible studies containing 1209 patients to include in the meta-analysis. Hazards ratios (HRs) with corresponding 95% confidence intervals (CIs) were pooled to estimate the association between lncRNA XIST expression and survival of cancer patients from Asian.ResultsThe result showed that higher lncRNA XIST expression in cancer tissue was related to a worse overall survival (OS) (HR = 1.54, 95% CI 1.07–2.23). In subgroup analysis, it revealed that lncRNA XIST overexpression was significantly associated with worse OS in digestive system tumors (HR = 1.67, 95% CI 1.11–2.51, p = 0.031). In addition, the association between high lncRNA XIST expression and poor OS was also statistically significant in other subgroups, including multivariate analysis (HR = 2.39, 95% CI 1.28–4.46, p = 0.006, random-effect), patients’ number was greater than 65 (HR = 1.75, 95% CI 1.24–2.47, p = 0.001, random-effect), and reported in text (HR = 2.50, 95% CI 1.49–4.18, p = 0.000, random-effect).ConclusionsThe expression of lncRNA XIST could be regarded as a poor prognostic biomarker for solid tumors, which might shed new light on epigenetic diagnostics and therapeutics in tumors.

Maternally expressed, paternally imprinted, embryonic non-coding RNA are expressed in osteosarcoma, Ewing sarcoma and spindle cell sarcoma

“…XIST, located on the X chromosome, has previously been reported as a poor prognostic marker in solid tumours. 8 We also found high expression of HCP5-204 that has previously been linked to cancer progression via sponging of miR-22, miR-186 and miR-216a. 9 MALAT1-203 and MALAT1-214, products of metastasis associated lung adenocarcinoma transcript 1 (MALAT1), were downregulated in this study (Table 1).…”

The mechanism of propofol in cancer development: An updated review

“…also proved that propofol promotes apoptosis in melanoma cells by suppressing the HOTAIR‐mediated mTOR/p70S6K signaling pathway . A recent study reported that the lncRNA XIST was dysregulated in different cancers and associated with poor clinical outcome . Chen et al.…”

“…It is well known that epigenetic alterations or genetic modulation of epigenetic regulators plays important roles in carcinogenesis . Many studies show that the anticancer effect of propofol is potentially due to regulation of the epigenetic pathway in cancer …”

“…30 A recent study reported that the lncRNA XIST was dysregulated in different cancers and associated with poor clinical outcome. [31][32][33][34] Chen et al…”

Prognostic and clinicopathologic significance of long non-coding RNA opa-interacting protein 5-antisense RNA 1 in multiple human cancers

“…LncRNAs could regulate a variety of cellular processes including proliferation, apoptosis, invasion, and angiogenesis and therefore exert a pivotal effect in aging, degeneration and carcinogenesis [7,8]. Of late, emerging evidence showed that lncRNAs (such as CASC2, ZEB1-AS1, XIST, and HOXA11-AS) were involved in regulation of cancer related genes and signalling pathways [9][10][11][12]. Meanwhile, numerous lncRNAs have been proved to have potential application as diagnostic biomarkers and therapeutic targets in human cancers [13][14][15][16].…”